Healthcare provider profile · identity verified

Fadi Bailony, MD

Internal Medicine · CINCINNATI, OH · NPI 1003965385

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	201	72
Amlodipine Besylate	Amlodipine Besylate	134	53
Omeprazole	Omeprazole	107	43
Levothyroxine Sodium	Levothyroxine Sodium	96	31
Gabapentin	Gabapentin	90	28
Lisinopril	Lisinopril	87	39
Fluticasone Propionate	Fluticasone Propionate	86	49
Pantoprazole Sodium	Pantoprazole Sodium	80	27
Ozempic	Semaglutide	77	19
Losartan Potassium	Losartan Potassium	73	27
Albuterol Sulfate Hfa	Albuterol Sulfate	70	27
Escitalopram Oxalate	Escitalopram Oxalate	65	32
Cephalexin	Cephalexin	64	56
Hydrochlorothiazide	Hydrochlorothiazide	52	18
Lamotrigine	Lamotrigine	52	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	52	26
Azithromycin	Azithromycin	51	46
Furosemide	Furosemide	50	20
Pravastatin Sodium	Pravastatin Sodium	49	16
Tamsulosin Hcl	Tamsulosin Hcl	49	23
Alprazolam	Alprazolam	48	suppressed
Potassium Chloride	Potassium Chloride	46	12
Simvastatin	Simvastatin	46	suppressed
Azelastine Hcl	Azelastine Hcl	43	33
Sertraline Hcl	Sertraline Hcl	42	18
Metoprolol Succinate	Metoprolol Succinate	40	20
Mounjaro	Tirzepatide	40	suppressed
Metformin Hcl	Metformin Hcl	39	19
Venlafaxine Hcl Er	Venlafaxine Hcl	38	13
Fluoxetine Hcl	Fluoxetine Hcl	37	12
Trazodone Hcl	Trazodone Hcl	36	13
Donepezil Hcl	Donepezil Hcl	33	14
Metformin Hcl Er	Metformin Hcl	33	16
Eliquis	Apixaban	31	suppressed
Methylprednisolone	Methylprednisolone	31	28
Methocarbamol	Methocarbamol	27	13
Allopurinol	Allopurinol	25	suppressed
Clopidogrel	Clopidogrel Bisulfate	24	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	24	20
Montelukast Sodium	Montelukast Sodium	24	13
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	11
Alendronate Sodium	Alendronate Sodium	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Carvedilol	Carvedilol	22	suppressed
Celecoxib	Celecoxib	22	suppressed
Mirtazapine	Mirtazapine	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	11
Trulicity	Dulaglutide	20	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	19	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Bupropion Xl	Bupropion Hcl	18	suppressed
Finasteride	Finasteride	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Diazepam	Diazepam	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Atenolol	Atenolol	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Temazepam	Temazepam	13	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Novolog	Insulin Aspart	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error